VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism
- Written by PR Newswire
- 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p <0.0001)
- Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug.
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- VISEN Pharmaceuticals, an...
